Dr. Mohammed Milhem, MBBS
Claim this profileUniversity of Iowa Hospitals and Clinics
Studies Melanoma
Studies Sarcoma
16 reported clinical trials
28 drugs studied
Area of expertise
1Melanoma
Stage IV
BRAF positive
Stage III
2Sarcoma
Stage IV
Stage III
archival tumor tissue
Affiliated Hospitals
Clinical Trials Mohammed Milhem, MBBS is currently running
TAB004 + Toripalimab
for Solid Cancers
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting1 award Phase 110 criteria
Gemcitabine + Ascorbate
for Sarcoma
This study will enroll patients who have a diagnosis of locally advanced, unresectable or metastatic soft tissue or bone sarcoma (except gastrointestinal stromal tumors and Kaposi's sarcoma) from any site.
Recruiting1 award Phase < 1
More about Mohammed Milhem, MBBS
Clinical Trial Related4 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Mohammed Milhem, MBBS has experience with
- Nivolumab
- Temozolomide
- RP1
- Vusolimogene Oderparepvec
- DF6002
- Chlorpromazine
Breakdown of trials Mohammed Milhem, MBBS has run
Melanoma
Sarcoma
Solid Tumors
Soft Tissue Sarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mohammed Milhem, MBBS specialize in?
Mohammed Milhem, MBBS focuses on Melanoma and Sarcoma. In particular, much of their work with Melanoma has involved Stage IV patients, or patients who are BRAF positive.
Is Mohammed Milhem, MBBS currently recruiting for clinical trials?
Yes, Mohammed Milhem, MBBS is currently recruiting for 11 clinical trials in Iowa City Iowa. If you're interested in participating, you should apply.
Are there any treatments that Mohammed Milhem, MBBS has studied deeply?
Yes, Mohammed Milhem, MBBS has studied treatments such as Nivolumab, Temozolomide, RP1.
What is the best way to schedule an appointment with Mohammed Milhem, MBBS?
Apply for one of the trials that Mohammed Milhem, MBBS is conducting.
What is the office address of Mohammed Milhem, MBBS?
The office of Mohammed Milhem, MBBS is located at: University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 United States. This is the address for their practice at the University of Iowa Hospitals and Clinics.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.